GlassScriptPhysician profile
Shon George Michael
NPI 1609182898
$1,815.27
in general payments reported to CMS, 2019-2025
21 companies · $80.64 in 2025
The $80.64 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $194 · 2021: $261 · 2022: $13.27 · 2023: $279 · 2024: $318 · 2025: $80.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.67 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $216.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $176.13 | 2019-2023 | Ultomiris |
| Biogen, INC. | $129.42 | 2021-2025 | Vumerity |
| Lilly USA, LLC | $124.27 | 2019 | |
| Ucb, INC. | $67.81 | 2019-2024 | Zilbrysq |
| Pfizer INC. | $62.64 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $62.08 | 2019 | |
| Allergan, INC. | $41.97 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $35.70 | 2020-2023 | Dysport |
| Genzyme Corporation | $35.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.74 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $27.46 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $27.23 | 2020-2024 | Crexont |
| Livanova USA, INC. | $19.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $16.41 | 2019 | |
| Tanabe Pharma America, INC. | $16.08 | 2019 | |
| Ge Healthcare | $15.49 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.50 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.19 | 2019 | |
| Akcea Therapeutics, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shon Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.